Literature DB >> 7644037

Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study.

K Andersen1, L J Launer, A Ott, A W Hoes, M M Breteler, A Hofman.   

Abstract

Based on reports that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for Alzheimer's disease (AD), we studied the cross-sectional relation between NSAID use and the risk for AD in a population-based study of disease and disability in older people. After controlling for age, education, gender, and use of benzodiazepines, we found a relative risk (RR) for AD of 0.38 (0.15 to 0.95) when comparing NSAID users (n = 365) to NSAID non-users (n = 5,893). To address confounding by indication or contraindication, we compared NSAID users with a subset of NSAID non-users who were using topical medication for ear, eye, or dermatologic conditions (n = 365). In this comparison, the adjusted RR for AD was 0.54 (0.16 to 1.78). These findings are compatible with a possible protective effect of NSAIDs on the risk for AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644037     DOI: 10.1212/wnl.45.8.1441

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 2.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

3.  Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype.

Authors:  J Cervilla; M Prince; S Joels; S Lovestone; A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

4.  Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer's disease risk in Chinese.

Authors:  Wenlu Tang; Meixia He; Bo Yang; Kankan Wei; Ming Yin; Lirong Zhang
Journal:  Neurol Sci       Date:  2012-05-24       Impact factor: 3.307

5.  Synthesis of Substituted N-[4(5-Methyl/phenyl-1,3,4-oxadiazol-2-yl)-3,6-dihydropyridin-1(2H)-yl]benzamide/benzene Sulfonamides as Anti-Inflammatory and Anti-Cancer Agents.

Authors:  Madhavi Gangapuram; Kinfe K Redda
Journal:  J Heterocycl Chem       Date:  2009-05-01       Impact factor: 2.193

Review 6.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 7.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 8.  Medications and diet: protective factors for AD?

Authors:  Claudia H Kawas
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jul-Sep       Impact factor: 2.703

9.  CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs : Therapeutic Implications.

Authors:  A Morgan; D Clark
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

10.  RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.

Authors:  Fang Fang; Lih-Fen Lue; Shiqiang Yan; Hongwei Xu; John S Luddy; Doris Chen; Douglas G Walker; David M Stern; Shifang Yan; Ann Marie Schmidt; John X Chen; Shirley ShiDu Yan
Journal:  FASEB J       Date:  2009-11-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.